We read with great interest the report of Gane et al.1 They evaluated the efficacy and safety of direct-acting antivirals, ledipasvir-sofosbuvir fixed dose combination, for chronic hepatitis C virus genotype 2 infection. The rate of sustained virologic response 12 weeks after the end of treatment was 96% (25/26) in the first cohort of hepatitis C virus genotype 2 patients receiving 12 weeks of treatment, but only 74% (20/27) in the second cohort with an 8-week regimen.